• Oncimmune is a leading early cancer detection company developing and commercialising its proprietary EarlyCDT platform technology
  • Oncimmune's EarlyCDT-Lung product can detect cancer up to four years earlier than other standard methods such as chest x-ray or Spiral CT
  • Oncimmune's EarlyCDT-Lung Technology Detects Autoantibodies - part of the body's natural immune response to cancer - and can be applied to wide rate of solid tumour types
  • Almost 80% of lung cancers are diagnosed after spread. Find lung cancer before symptoms appear. EarlyCDT-Lung combined with CT can help.